Navigation Links
New Findings of Daily Consumption of Soy Isoflavones and Cacao-Flavonoids in Diabetes Type 2 Patients
Date:5/4/2012

ZURICH, May 4, 2012 /PRNewswire/ --



A new, one-year, double-blind controlled clinical study shows that cacao-flavonoids and soy isoflavones can significantly improve biomarkers of CVD risk in postmenopausal women with type 2 diabetes[1].

The trial, conducted by Peter J. Curtis, Ph.D., et al, funded by a UK based Charity, Diabetes UJK, and supported by Frutarom Ltd., Israel, and Barry Callebaut, the world's leading manufacturer of high-quality cocoa and chocolate products, was published February, 2012, in Diabetes Care. The purpose of the study was to assess the effect of dietary flavonoids on cardiovascular disease (CVD) risk in postmenopausal women with type 2 diabetes on established statin and hypoglycemic therapy.

The clinical trial consisted of 93 medicated postmenopausal women with type 2 diabetes. Subjects were randomly allocated to consume 27 g/day (split dose) of flavonoid-enriched chocolate (Barry Callebaut ACTICOA™ chocolate containing 850 mg flavan-3-ols [90 mg epicatechin] and 100 mg of isoflavones [aglycone equivalents)]/day) or a matched placebo.

At the conclusion of this trial, the combined one-year intervention with flavan-3-ols and isoflavones resulted in a significant improvement in biomarkers of CVD risk in postmenopausal type 2 diabetic patients, compared to placebo. These data highlight the additional benefit of dietary flavonoids to standard drug therapy in managing CVD risk in this group of patients.

"We are incredibly happy with the new study results showing that the soy isoflavones in SoyLife®, produced by Frutarom, in combination with cacao-flavonoids could help decrease CVD risk," says Mira Koppert, Manager of the LifeLine brand extension at Frutarom. "We anticipate these outstanding findings will open new opportunities in marketing SoyLife to supplement makers and food processors and position it as the leading soy isoflavones source in the global market."

SoyLife has been included in more than 35 proprietary studies in the fields of menopause, bone health, heart health, and cognitive function. "SoyLife stands out in the market in comparison to other soy isoflavones, not only due to its extensive research but also because it is a natural, multi-component ingredient, derived from soy germ, containing not just soy isoflavones but also vitamin E, antioxidants, fibre and many others," explains Mira Koppert. "These factors and the typical soy germ isoflavone profile of genistein : daidzein : glycitein, which is 15 : 50 : 35 indicate SoyLife is a perfect solution to obtain the health effects associated with soy." SoyLife is available in concentrations ranging from 3% to 40% and can be used in tablets, capsules, soft-gel capsules, as well as multiple functional food and beverage applications. For more information, visit the new SoyLife website at http://www.soylife.com

About Frutarom

Frutarom's vision is to become the preferred partner for tasty and healthy success, reflecting its commitment to deliver the most flavorful and healthful solutions to our customers. Frutarom sees research and innovation as a core competency and its global R&D team benefits from a wealth of experience accumulated over 75 years. The company has the distinct advantage of a broad range of in-house raw materials and close collaborations with universities, research institutes and start-ups.

Meet us at VitaFoods booth no. 2134 & SupplySide MarketPlace booth no. 327

For further information, please contact:

Company contact

Health Business Unit
Frutarom Switzerland Ltd.
Mira Koppert
Product Manager LifeLine
Tel +41-44-782-6572
Frutarom Switzerland Ltd., 8820 Wädenswil
Email: Marketing_Health@Frutarom.com
Web: http://www.frutarom.com

Press Contact

MARKETARGET
Liat Simha
Tel: +972-3-9381107
E-mail:  ls@market-targets.com

1. Curtis P. J. et al, Chronic Ingestion of Flavan-3-ols and Isoflavones Improves Insulin Sensitivity and Lipoprotein Status and Attenuates Estimated 10-Year CVD Risk in Medicated Postmenopausal Women With Type 2  Diabetes, Diabetes Care 2012, 35, 226 - 232.



'/>"/>
SOURCE Frutarom Industries Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Profil Institute Continues to Publish New Findings in Metabolic Research
2. Expanded Findings for FirstMarks Completed Clinical Study for Predicting Near-Term (2-3 Years) MI
3. GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI)
4. Live Press Briefing on Findings of Biomedical Industry CEO Survey
5. 23andMe Presents Top Ten Most Interesting Genetic Findings of 2011
6. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
7. New Findings Reported by TJ Gan and Authors from Duke Anesthesiology Demonstrate Efficacy of Cheetah Medicals NICOM® Bioreactance® Technology to Guide Goal Directed Intraoperative Therapy
8. Otonomy Presents Positive New Findings From Phase 1b Study of OTO-104 in Menieres Disease at International Conference
9. The Human Brain is Sensitive to Light, Breakthrough Findings From Valkee and the University of Oulu
10. Researchers From More Than 30 Countries Share Findings About the Use of Ultrasound in the Prevention, Diagnosis and Treatment of Heart Disease
11. New findings by UCR scientists hold big promise for fight against mosquito-borne diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... HOLLOWAY AMERICA, a leading custom ... Rocky Mountain Chapter 21st Annual Vendor Exhibition on Thursday, February 18, 2016. The ... for its annual event, which will run from 3:00 p.m. - 8:30 p.m. ...
(Date:2/10/2016)... ... February 10, 2016 , ... SonaCare ... training and support program, Sonalink™ remote monitoring. The inaugural launch of this new ... February 5th, connecting Dr. Samuel Peretsman to a HIFU technical expert at SonaCare ...
(Date:2/10/2016)... ... February 10, 2016 , ... Curoverse announced today that ... Arvados provides capabilities for managing and processing genomic and health data at petabyte ... institutions collecting and analyzing genomic data,” said Adam Berrey chief executive officer at ...
(Date:2/10/2016)... Jolla CA (PRWEB) , ... February 10, 2016 , ... ... new agents for the treatment of Alzheimer’s disease, announced today it has been selected ... February 18th at the Breakers in Palm Beach, Florida. The purpose of the ...
Breaking Biology Technology:
(Date:2/3/2016)... Feb. 3, 2016 ... of the "Emotion Detection and Recognition ... and Others), Software Tools (Facial Expression, Voice ... Users,and Regions - Global forecast to 2020" ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the ...
(Date:2/2/2016)... Feb. 2, 2016 Checkpoint Inhibitors for ... Market Are you interested in the future ... for checkpoint inhibitors. Visiongain,s report gives those predictions ... and national level. Avoid falling behind in ... opportunities and revenues those emerging cancer therapies can ...
(Date:2/2/2016)... MOUNTAIN VIEW, Calif. , Feb. 2, 2016 ... diabetic retinopathy market, Frost & Sullivan recognizes US-based ... North America Frost & Sullivan Award for New ... technology provider in North America ... standard in the rapidly growing diabetic retinopathy market. ...
Breaking Biology News(10 mins):